Superworth

Viking Therapeutics EPS VKTX

Diluted earnings per share by quarter and over the last twelve months, from 2014.

Last 12 months, to Jun 30, 2026
−$4.66
Latest quarter, Q2 FY26
−$1.10
Fiscal year 2025
−$3.18

Viking Therapeutics' earnings per share was −$4.66 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$1.10.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$3.18n/a
FY2024−$1.00n/a
FY2023−$0.92n/a
FY2022−$0.91n/a
FY2021−$0.72n/a
FY2020−$0.54n/a
FY2019−$0.36n/a
FY2018−$0.41n/a
FY2017−$0.80n/a
FY2016−$1.00n/a
FY2015−$4.01n/a
FY2014−$5.25n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$1.10n/a−$4.66
Q1 FY26−$1.37n/a−$4.14
Q4 FY25−$1.38n/a−$3.18
Q3 FY25−$0.81n/a−$2.12
Q2 FY25−$0.58n/a−$1.53
Q1 FY25−$0.41n/a−$1.15
Q4 FY24−$0.32n/a−$1.00
Q3 FY24−$0.22n/a−$0.93
Q2 FY24−$0.20n/a−$0.94
Q1 FY24−$0.26n/a−$0.93
Q4 FY23−$0.25n/a−$0.92
Q3 FY23−$0.23n/a−$0.93

Against its peers

Companies in Drug Manufacturers - General nearest Viking Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
VKTXViking Therapeutics−$4.66
NRIXNurix Therapeutics$2.31
PBHPrestige Consumer Healthcare$3.57−16% a year
OGNOrganon$0.77−71% a year
LQDALiquidia$1.39
HRMYHarmony Biosciences$3.09−0% a year
ARQTArcutis Biotherapeutics$0.22
INDVIndivior Pharmaceuticals$2.78+227% a year
ANIPANI Pharmaceuticals$4.70
PAHCPhibro Animal Health$2.44+107% a year
ANABAnaptysbio$4.57
Peer median$2.61

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Viking Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.